- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05290194
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
13. april 2022 opdateret af: Zhigang Liu, Fifth Affiliated Hospital, Sun Yat-Sen University
Multi-target Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine Maintenance Therapy Treating Oligometastatic Nasopharyngeal Carcinoma: a Single-arm, Multicenter, Prospective, Open-label Phase II Clinical Trial
This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal carcinoma, the main purpose of which is to evaluate the efficacy of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal carcinoma.
Studieoversigt
Status
Rekruttering
Detaljeret beskrivelse
This is a single-arm, multicenter, prospective, open-label phase II clinical study of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy for oligometastatic nasopharyngeal carcinoma.
Its primary objective is to assess the efficacy, including progression-free survival (PFS), 2-year overall survival (Two-year OS) and progression-free survival (Two-year PFS), overall survival (OS), duration of response (DOR) and safety of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy in treating oligometastatic nasopharyngeal carcinoma.
The secondary objective is to explore the potential genetic biomarkers and clinical therapeutic efficacy evaluation and prediction model of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal carcinoma, providing the evidence of the screening of the potential patients benefiting from the regimen of this trial.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
28
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Zhigang MD Liu, PhD
- Telefonnummer: 2528888
- E-mail: zhigangliu1983@hotmail.com
Undersøgelse Kontakt Backup
- Navn: Zhigang MD Liu, PhD
- Telefonnummer: 2528888
- E-mail: liuzhg9@mail.sysu.edu.cn
Studiesteder
-
-
Guangdong
-
Zhuhai, Guangdong, Kina
- Rekruttering
- Fifth Affilliated Hospital of Sun Yat-sen University
-
Kontakt:
- Zhigang Liu, M.D.
- Telefonnummer: +86 18627585860
- E-mail: zhigangliu1983@hotmail.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 70 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- The patient was histologically or cytologically diagnosed with nasopharyngeal carcinoma;
- The patient was newly diagnosed with metastatic nasopharyngeal carcinoma (AJCC eighth edition), and after 4-6 cycles of gemcitabine plus cisplatin combined with PD-1 monoclonal antibody regimen, the efficacy reached more than stable disease;
- Except for the primary tumor and cervical lymph node metastasis, less than 5 distant organ metastases, and were suitable for SBRT radiotherapy;
- ECOG PS score 0-2 points;
- Aged 18-70 years old;
Major organ function met the following criteria (14 do not allow the use of any blood components and cell growth factor):
- Neutrophil ANC ≥ 2.0 × 10^9/L; platelet count PLT ≥ 100 × 10^9/L; hemoglobin HB ≥ 90 g/L;
- Serum albumin ≥ 28 g/L;
- Alanine aminotransferase ALT, aspartate aminotransferase AST ≤ 2.5 × ULN; if there is liver metastasis, ALT and AST ≤ 5 × ULN;
- Serum creatinine ≤ 1.5 × ULN, Or creatinine clearance ≥ 60 mL/min;
- INR ≤ 1.5 × ULN, and APTT ≤ 1.5 × ULN;
- Life expectancy ≥ 12 weeks;
- The subject who voluntarily joins the study, sign informed consent, and coordinates with follow-up.
Exclusion Criteria:
- Recurrent and metastatic nasopharyngeal carcinoma after initial treatment;
- Patients received previous treatment of primary lesion or metastasis except for the standard first-line regimen (gemcitabine plus cisplatin combined with PD-1 monoclonal antibody regimen), including induction chemotherapy, adjuvant chemotherapy, concurrent chemoradiotherapy, surgery and other treatments;
- Central nervous system metastastic (confirmed or suspected);
- Allergy to PD-1 monoclonal antibody or other PD-1 monoantibody; intolerance or allergy to capecitabine; suffering any disease or extrinsic factors affecting oral drugs;
- Uncontrolled cardiac clinical symptoms or diseases, such as: ① heart failure of NYHA Grade II or higher ; ② unstable angina pectoris; ③ suffering myocardial infarction within 1 year; ④ patients with supraventricular or arrhythmia requiring clinical intervention;
- Severe infection (CTCAE 5.0 ≥ 2) 4 weeks before the first use of study drugs, such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging examination suggests the presence of active pulmonary inflammation; symptoms and signs of infection or the need for oral or intravenous antibiotics (excluding the prophylactic use of antibiotics) 2 weeks before the first use of the study drug;
- History of other malignancies within 5 years or at the time,but except for cured cutaneous basal cell carcinoma and cervical carcinoma in situ, breast carcinoma in situ, superficial bladder tumors (Ta, Tis and T1) and papillary thyroid cancer as well as other cancers treated more than 3 years before the start of the study;
Any of the following conditions is met:
- Received any investigational drug before the first use of the study drug;
- Participated in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or interventional clinical study at the follow-up time;
- Required systemic treatments with corticosteroids (the dose higher than the equivalent dose of 10 mg prednisone per day) or other immunosuppressive agents 2 weeks before the first use of the study drug, except for local inflammation and prevention of allergy and nausea and vomiting. In the absence of active autoimmune disease, inhaled or topical steroids and adrenocorticotropic hormone replacement at doses greater than 10 mg daily in prednisone efficacy dose are allowed;
- Received anti-tumor vaccines or vaccinated live vaccines 4 weeks before the first dose of study drug;
- Underwent excessive surgery or severe trauma 4 weeks before the first use of study drug;
- Patients had active autoimmune diseases and a history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes) in the past 2 years; patients who did not require any intervention after adulthood are allowed;
- History of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;
- Patients with active pulmonary tuberculosis infection found by medical history or CT examination, or with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or with a history of active pulmonary tuberculosis infection 1 year ago but without regular treatment;
- Patients with active hepatitis (HBV ≥ 2000 IU/ml or HBV DNA ≥ 10000/ml), or hepatitis C (hepatitis C antibody positive, and HCV-RNA ≥ 1000/ml);
- Patients with coagulation abnormalities (PT > 16s, APTT > 43s, TT > 21s, Fbg < 2 g/L), bleeding tendency or receiving thrombolytic or anticoagulant therapy; or patients with previous severe bleeding (bleeding > 30ml within 3 months), hemoptysis (bleeding > 5ml within 4 weeks) within 12 months due to thromboembolic events (including stroke events and/or transient ischemic attack);
- Uncontrolled hypertension (systolic blood pressure > 140 mmHg, or diastolic blood pressure > 90 mmHg); coronary heart disease, arrhythmia ≥ grade II (including QTc prolongation, male > 450 ms, female > 470 ms) and heart failure;
- Urine protein ≥ + +, or 24 hour urine protein ≥ 1.0 g;
- Current diarrhea-related diseases (e.g., ulcerative colitis, Crohn's disease, chronic diarrhea, etc.);
- Known history of psychotropic drug abuse, alcoholism and drug abuse; or current history of antiepileptic drug use;
- Pregnant or lactating;
- Patients considered unsuitable for inclusion by the investigator as assessed by the investigator.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Oligometastatic nasopharyngeal carcinoma
Patients included are going to receive radiotherapy, chemotherapy and immunotherapy.
Radiotherapy includes IMRT and SBRT.
IMRT is applied for primary sites and cervical lymph nodes,and SBRT following is applied for oligometastatic sites.
PD-1 inhibitors: during the whole trial, intravenous, Q3W; Capecitabine: 650mg, po, bid, following the radiotherapy for a year.
|
Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.
Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
Andre navne:
Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Progress-free survival
Tidsramme: 2 years
|
The time between enrollment and progression(in any way) or death (for any reason)
|
2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall survival
Tidsramme: 2years
|
Time from randomization to death (for any reason)
|
2years
|
Duration of response
Tidsramme: 2 yaers
|
Time from the first evaluation of the tumor as CR or PR to the first evaluation as PD or death from any cause
|
2 yaers
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Tidsramme: 2 years
|
The incidence of adverse events (≥Grade 2,CTCAE V5.0)
|
2 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Zhigang MD Liu, PhD, Fifth Affilliated Hospital of Sun Yat-sen University
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
28. marts 2022
Primær færdiggørelse (Forventet)
1. december 2026
Studieafslutning (Forventet)
1. januar 2027
Datoer for studieregistrering
Først indsendt
5. marts 2022
Først indsendt, der opfyldte QC-kriterier
20. marts 2022
Først opslået (Faktiske)
22. marts 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
14. april 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
13. april 2022
Sidst verificeret
1. april 2022
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer efter sted
- Neoplasmer, kirtel og epitel
- Pharyngeale neoplasmer
- Otorhinolaryngologiske neoplasmer
- Neoplasmer i hoved og hals
- Nasopharyngeale sygdomme
- Pharyngeale sygdomme
- Stomatognatiske sygdomme
- Otorhinolaryngologiske sygdomme
- Nasopharyngeale neoplasmer
- Karcinom
- Nasopharyngealt karcinom
- Molekylære mekanismer for farmakologisk virkning
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Capecitabin
- Immune Checkpoint-hæmmere
Andre undersøgelses-id-numre
- ZDWY[2022]LunziNo.(K11-1)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
UBESLUTET
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Nasopharyngealt karcinom
-
National Cancer Institute (NCI)AfsluttetNivolumab til behandling af patienter med tilbagevendende og/eller metastatisk nasopharyngeal cancerTilbagevendende nasopharynx carcinom | Stadie III Nasopharyngeal Carcinoma AJCC v7 | Stadie IV Nasopharyngeal Carcinoma AJCC v7 | Stadie IVA Nasopharyngeal Carcinoma AJCC v7 | Stadie IVB Nasopharyngeal Carcinoma AJCC v7 | Stadie IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal ikke-eratiniserende...Forenede Stater, Singapore, Kina
-
National Cancer Institute (NCI)RekrutteringStadie IV Nasopharyngeal Carcinoma AJCC v8 | Fase II Nasopharyngeal Carcinoma AJCC v8 | Stadie III Nasopharyngeal Carcinoma AJCC v8Forenede Stater
-
National Cancer Institute (NCI)NRG OncologyAfsluttetTilbagevendende nasopharyngeal karcinom | Stadie IV Nasopharyngeal Carcinoma AJCC v8 | Metastatisk nasopharyngeal karcinom | Metastatisk nasopharyngeal keratiniserende planocellulær karcinom | Metastatisk nasopharyngealt ikke-eratiniserende karcinom | Metastatisk nasopharyngeal udifferentieret... og andre forholdForenede Stater, Canada, Kina, Singapore
-
Alliance for Clinical Trials in OncologyIkke rekrutterer endnuTilbagevendende nasopharyngeal karcinom | Stadie IV Nasopharyngeal Carcinoma AJCC v8 | Metastatisk nasopharyngeal karcinom
-
National Cancer Institute (NCI)RekrutteringTilbagevendende nasopharyngeal karcinom | Stadie IV Nasopharyngeal Carcinoma AJCC v8 | Metastatisk nasopharyngeal karcinomForenede Stater, Kina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbagevendende peritoneal malignt mesotheliom | Tilbagevendende Malignt lungehindekræft | Vaginalt planocellulært karcinom, ikke andet specificeret | Neuroendokrint karcinom | Pancreas neuroendokrin tumor | Tilbagevendende Merkelcellekarcinom | Tilbagevendende nasopharynx carcinom | Tillæg Adenocarcinom og andre forholdForenede Stater
-
Fujian Cancer HospitalIkke rekrutterer endnuNasopharyngeal Carcinoma af AJCC V8 Stage
-
Fourth Affiliated Hospital of Guangxi Medical UniversityGuilin Medical University, China; Wuzhou Red Cross Hospital; Second Affiliated... og andre samarbejdspartnereRekrutteringNasopharyngeal Carcinoma af AJCC V8 StageKina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrutteringKlinisk trin III HPV-medieret (p16-positiv) orofaryngealt karcinom AJCC v8 | Stadium III Hypopharyngeal Carcinom AJCC v8 | Fase III Larynxcancer AJCC v8 | Stadie III Oropharyngeal (p16-negativ) karcinom AJCC v8 | Stadie IV Hypopharyngeal Carcinom AJCC v8 | Fase IV Larynxcancer AJCC v8 | Stadie IV... og andre forholdForenede Stater
-
Chongqing University Cancer HospitalRekrutteringNasopharyngeal Carcinoma af AJCC V8 StageKina
Kliniske forsøg med SBRT radiotherapy + Conventionally fractionated radiotherapy
-
Ottawa Hospital Research InstituteAfsluttetPancreascarcinom Ikke-operabeltCanada
-
University Hospital HeidelbergRekrutteringMagnetisk resonans-guidet adaptiv stereootaktisk kropsstrålebehandling til levermetastaser (MAESTRO)Hepatisk metastaseTyskland
-
Cancer Trials IrelandUniversity College Dublin; Technological University DublinRekrutteringNSCLC/Oligometastatisk kræft (enkelt lungelæsion)Irland
-
European Institute of OncologyAssociazione Italiana per la Ricerca sul CancroRekrutteringAdenocarcinom i prostataItalien
-
Institut für Klinische Krebsforschung IKF GmbH...AstraZeneca; Thoraxklinik-Heidelberg gGmbHRekruttering
-
Memorial Sloan Kettering Cancer CenterRekrutteringNon-Hodgkin lymfom | Non-Hodgkins lymfom, tilbagefald | Non-Hodgkins lymfom refraktærForenede Stater
-
RefleXion MedicalAfsluttetKræft | Tumor, fast | Kræft, lunge | Metastase til knogle | Metastase til lunge | Kræft, BoneForenede Stater
-
Sunnybrook Health Sciences CentreRekrutteringGlioblastom, IDH-mutant | Glioblastoma Multiforme, voksenCanada
-
General University Hospital, PragueIkke rekrutterer endnu
-
Ottawa Hospital Research InstituteUkendt